恩替诺特增强奥拉帕利对同源重组 proficient 卵巢癌的疗效
该临床前研究评估组蛋白去乙酰化酶抑制剂恩替诺特联合PARP抑制剂奥拉帕利在HR proficient卵巢癌细胞及动物模型中的作用。结果显示联合用药可降低细胞活力、减少腹膜转移、延长CCNE1扩增PDX模型生存期,机制涉及下调BRCA1、阻滞复制叉及增加DNA损伤。为HR proficient卵巢癌(含CCNE1扩增亚型)的临床试验提供依据。
要点
- 恩替诺特增强奥拉帕利对HR proficient卵巢癌细胞的杀伤作用
- 联合用药在SKOV-3异种移植模型中减少腹膜转移
- 在CCNE1扩增PDX模型中联合用药延长生存期
核心结论
- 恩替诺特通过降低BRCA1表达和阻滞复制叉进展抑制HR修复,导致不可修复的DNA损伤和细胞死亡。
- 该联合方案为HR proficient卵巢癌(包括CCNE1扩增亚型)的临床试验提供临床前支持。
研究设计与样本
- 体外实验使用SKOV-3、OVCAR-3细胞系及CCNE1扩增高 Grade 浆液性卵巢癌患者原代细胞。
- 体内实验使用SKOV-3异种移植模型和CCNE1扩增HR proficient患者来源异种移植(PDX)模型。
主要发现
- 恩替诺特增强奥拉帕利降低HR proficient卵巢癌细胞活力和克隆形成能力的效果。
- 联合用药在SKOV-3异种移植模型中减少腹膜转移。
- 联合用药在CCNE1扩增HR proficient PDX模型中延长生存期。
- 恩替诺特增强奥拉帕利诱导的DNA损伤。
- 恩替诺特降低BRCA1表达,伴随Ki-67下降和cleaved PARP增加。
临床怎么用
- 支持在复发HR proficient卵巢癌中开展奥拉帕利联合恩替诺特的I/II期临床试验。
- 提示CCNE1扩增亚型也可能从该联合方案中获益。
局限性
- 本研究为临床前数据,尚未在临床试验中验证疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Poly ADP ribose polymerase inhibitors (PARPi) are most effective in BRCA1/2 mutated ovarian tumors. Better treatments are needed for homologous recombination HR-proficient cancer, including CCNE1 amplified subtypes. We have shown that histone deacetylase inhibitors (HDACi) sensitize HR-proficient ovarian cancer to PARPi. In this study, we provide complementary preclinical data for an investigator-initiated phase 1/2 clinical trial of the combination of olaparib and entinostat in recurrent, HR-proficient ovarian cancer. METHODS: We assessed the in vitro effects of the combination of olaparib and entinostat in SKOV-3, OVCAR-3 and primary cells derived from CCNE1 amplified high grade serous ovarian cancer (HGSOC) patients. We then tested the combination in a SKOV-3 xenograft model and in a patient-derived xenograft (PDX) model. RESULTS: Entinostat potentiates the effect of olaparib in reducing cell viability and clonogenicity of HR-proficient ovarian cancer cells. The combination reduces peritoneal metastases in a SKOV-3 xenograft model and prolongs survival in a CCNE1 amplified HR-proficient PDX model. Entinostat also enhances olaparib-induced DNA damage. Further, entinostat decreases BRCA1, a key HR repair protein, associated with decreased Ki-67, a proliferation marker, and increased cleaved PARP, a marker of apoptosis. Finally, entinostat perturbs replication fork progression, which increases genome instability. CONCLUSION: Entinostat inhibits HR repair by reducing BRCA1 expression and stalling replication fork progression, leading to irreparable DNA damage and ultimate cell death. This work provides preclinical support for the clinical trial of the combination of olaparib and entinostat in HR-proficient ovarian cancer and suggests potential benefit even for CCNE1 amplified subtypes.
引用
- Gupta VG, Hirst J, Petersen S, et al. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gynecol Oncol. 2021. PMID: 33867143. doi:10.1016/j.ygyno.2021.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。